KIN

Kindred Bio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.500
-0.500
-12.50%
Closed 16:06 04/01 EDT
OPEN
3.980
PREV CLOSE
4.000
HIGH
3.980
LOW
3.350
VOLUME
178.83K
TURNOVER
--
52 WEEK HIGH
11.93
52 WEEK LOW
3.105
MARKET CAP
137.51M
P/E (TTM)
-2.2026
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average KIN stock price target is 13.93 with a high estimate of 25.00 and a low estimate of 9.00.

EPS

KIN News

More
  • Edited Transcript of KIN earnings conference call or presentation 16-Mar-20 8:30pm GMT
  • Thomson Reuters StreetEvents · 3d ago
  • Kindred fusion protein shows positive effect in dogs with atopic dermatitis
  • Seeking Alpha - Article · 03/24 14:06
  • Kindred Biosciences Announces Positive Results from Pilot Field Efficacy Study of its IL-4/IL-13 SINK Molecule Being Developed for the Treatment of Atopic Dermatitis in Dogs
  • PR Newswire · 03/24 13:31
  • Kindred Biosciences, Inc. Just Reported Earnings, And Analysts Cut Their Target Price
  • Simply Wall St. · 03/18 11:53

Industry

Biotechnology & Medical Research
-4.52%
Pharmaceuticals & Medical Research
-2.91%

Hot Stocks

Symbol
Price
%Change

About KIN

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company's lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company's other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.
More

Webull offers kinds of Kindred Biosciences Inc stock information, including NASDAQ:KIN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KIN stock news, and many more online research tools to help you make informed decisions.